Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Abstract

GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral bioavailability of GS‐441524 poses a challenge to its anti-SARS-CoV-2 efficacy. Remdesivir, the intravenously administered version (version 1.0) of GS-441524, is the first FDA-approved agent for SARS-CoV-2 treatment. However, clinical trials have presented conflicting evidence on the value of remdesivir in COVID-19. Therefore, oral GS-441524 derivatives (VV116, ATV006, and GS-621763; version 2.0, targeting highly conserved viral RdRp) could be considered as game-changers in treating COVID-19 because oral administration has the potential to maximize clinical benefits, including decreased duration of COVID-19 and reduced post-acute sequelae of SARS-CoV-2 infection, as well as limited side effects such as hepatic accumulation. This review summarizes the current research related to the oral derivatives of GS-441524, and provides important insights into the potential factors underlying the controversial observations regarding the clinical efficacy of remdesivir; overall, it offers an effective launching pad for developing an oral version of GS-441524.

Extracellular Vesicle-Based SARS-CoV-2 Vaccine

“…Because the genome of SARS-CoV-2 is RNA-based, it consists of the following steps. (iv-a) Synthesis of RNA-dependent RNA polymerase (RdRp): SARS-CoV-2, which has (+)-strand RNA in its genome, first synthesizes RdRp encoded in the viral genome using host ribosomes [ 42 , 43 , 44 , 45 , 46 , 47 ]. Unlike DNA-dependent RNA polymerases in the host nucleus, RdRp is an enzymatic protein that synthesizes new RNA while reading the RNA sequence of the viral genome.…”

Biobran/MGN-3, an Arabinoxylan Rice Bran, Protects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An In Vitro and In Silico Study

“…Different types of natural products and herbal components have been examined for their potential use against SARS-CoV-2 [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. These include scutellarein, caffeic acid, myricetin, quercetin, saikosaponin B2, silvestrol, tryptanthrin, psoralidin, lectins such as griffithsin, isobavachalcone, and steroids [ 16 , 17 ].…”

Traditional Tibetan medicine to fight against COVID-19: Basic theory and therapeutic drugs

“…Its negative impacts on the global economy and healthcare system are immeasurable and still ongoing. Healthcare systems in different countries are struggling to control the virus and prevent the spread of COVID-19 ( Wang and Yang, 2021 ; Wang et al, 2022a ; Jayk Bernal et al, 2022 ; Tomalka et al, 2022 ). Obviously, there is an urgent need to seek safe and effective drugs or adjunctive therapies against COVID-19 ( Riva et al, 2020 ; Wang and Yang, 2020 ; 2022a ; Yang and Wang, 2021 ; Wang et al, 2022b ; Cully, 2022 ; Gao et al, 2022 ).…”